Al-Quds Pharmaceutical Company Achieves Record Profits in the First Half of 2025 Approaching 4 Million Dollars

SadaNews - The financial data published by Dr. Samih Al-Attout for Al-Quds Pharmaceutical Company, disclosed for the first half of 2025, shows significant improvement in performance, largely attributed to a considerable increase in sales with a growth rate of nearly 27%.

An important factor indicating the management's efficiency in cost management is the profit margin, which rose to 56% from 50% during the same period in 2024. With the increase in sales, management was able to reduce administrative and general expenses by nearly 3% compared to the same period in 2024.

The company's stock was trading at a market price as of June 30 at $3.88 per share, with the book value based on the first half data reaching $4.3 per share. The company is trading at an excellent price-to-earnings ratio of 10 times, which is very attractive for investment.

This is due to a significant improvement in profitability recently as a result of increased export sales and improved profit margins. The company achieved comprehensive profit exceeding $8 million, derived from currency price differentials due to the decline in the dollar's value against the shekel, which improves the company's profitability due to its sales in Israeli shekels. The company also achieved positive operating cash flows approaching $6 million during the first half of 2025.